Table 1.
Cell-line run controls
| Name | Origin | Treatment | Control | Provider |
|---|---|---|---|---|
| Jurkat | Human acute lymphocytic leukemia | 200 nM PMA for 15 min | Positive for AKT, ERK1/2, and MEK1/2 phosphorylation | Indivumed GmbH |
| Jurkat | Human acute lymphocytic leukemia | 1 µM staurosporine and 50 µM LY294002 for 2.5 h | Negative for AKT, ERK1/2, MEK1/2 phosphorylation | Indivumed GmbH |
| HT29 | Human colon adenocarcinoma | Untreated | Positive for c-MET phosphorylation | Indivumed GmbH |
| HT29 | Human colon adenocarcinoma | Calf intestinal alkaline phosphatase for 50 min | Negative for c-MET phosphorylation | Indivumed GmbH |
Compound-treated and compound-untreated cell lines have were as positive and negative controls for protein phosphorylation in order to control run quality. Compound treatment of cell lines is shown